News Search Results
Sep 17, 2025, 21:00 ET Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
myasthenia gravis (gMG). About Vor Bio Vor Bio is a clinical-stage biotechnology company committed to the treatment of autoimmune diseases. The company focuses on rapidly advancing the Phase III clinical development and commercialization
More news about: RemeGen Co., Ltd
Sep 17, 2025, 19:30 ET Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
rights in Greater China. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Sep 17, 2025, 18:01 ET Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Sep 17, 2025, 17:09 ET MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.
China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical data of an mRNA-lipid nanoparticle
More news about: Shenzhen MagicRNA Biotech Co., Ltd.
Sep 17, 2025, 14:47 ET Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome
MONTREAL, Sept. 17, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced that the U.S. Food
More news about: Thryv Therapeutics Inc.
Sep 17, 2025, 14:00 ET Bio Protocol Raises $6.9M to Launch AI-Native Decentralized Science Platform for Biotech Funding & Drug Discovery
2025 /PRNewswire/ -- Bio Protocol, the decentralized science (DeSci) platform building AI-native infrastructure for biotechnology, today announced it has raised $6.9 million in a funding round anchored by Maelstrom Fund, with participation from
More news about: BIO.XYZ
Sep 17, 2025, 12:00 ET Terra Oleo Emerges from Stealth with US$3.1M in Funding and Breakthrough Energy Fellow Selection to Reinvent Fats and Oils
Sept. 17, 2025 /PRNewswire/ -- Terra Oleo, a Singapore-based biotechnology company, today announced its emergence from stealth with US$3.1 million in funding from a group of investors, and
More news about: Terra Oleo
Sep 17, 2025, 11:51 ET Aker-Nscale JV signs Multi-Billion Dollar AI infrastructure agreement with Microsoft
Norway. Founded in 1841, Aker builds and develops leading companies across energy, industrial software, renewables, and marine biotechnology. As the largest shareholder in several listed and privately held companies, Aker combines deep industrial expertise, financial strength, and capital
More news about: Aker ASA
Sep 17, 2025, 11:31 ET Flagship Pioneering Appoints Mary Beth Harler President of Pioneering Medicines
in-house drug discovery and development unit. Dr. Harler comes to Flagship with more than two decades of senior leadership experience across the biotechnology and global pharmaceutical industries, spanning clinical development, organizational building, and corporate strategy.
More news about: Flagship Pioneering
Sep 17, 2025, 10:50 ET E-Cigarette Market Is Projected to Reach US$ 52.13 Billion By 2031 With A CAGR Of 10.8% |The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 17, 2025, 10:40 ET Digital Health Market Is Projected to Reach US$ 1921.38 Billion By 2031 With CAGR Of 25.7% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 17, 2025, 10:32 ET Radiance Technologies, LSU Health Shreveport, and LA Tech Unite for $5.85M DARPA Contract to Fuel Defense Biology Innovations
Radiance's first collaboration with DARPA BTO and establishes North Louisiana as an emerging hub for cutting-edge biotechnology research. The project, named "Crowded, Heterogeneous, Intracellular, and Multi-Scale Environments for Revolutionary Bio-Applications (CHIMERA)," aims
More news about: Radiance Technologies
Sep 17, 2025, 10:24 ET Anti-Money Laundering Market Is Projected to Reach US$ 13.54 Billion By 2031 with CAGR Of 18.3% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 17, 2025, 10:12 ET Global EV Battery Recycling Market Predicted to Reach $24.5 Billion by 2035 with CAGR 40.80% | A Strategic Inflection Point for Circular Economy, EV Sustainability, and Energy Security
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Sep 17, 2025, 09:42 ET Lung Cancer Pioneer Dr. Gilberto Lopes Joins Longevity Company Immorta Bio
the translation of this innovative science to patients." About Immorta BioImmorta Bio Inc. is a longevity-focused biotechnology company developing personalized cellular and immune therapeutics aimed at "Treating Diseases of Aging and Treating Aging as Disease™." The
More news about: Immorta Bio Inc.
Sep 17, 2025, 09:00 ET Mana.bio Unveils Mina™,The World's First Large Language Model-Powered AI Agent for Lipid Nanoparticles
TEL AVIV, Israel, Sept. 17, 2025 /PRNewswire/ -- Mana.bio, a biotechnology company pioneering the intersection of artificial intelligence and RNA delivery, today announced the launch of Mina™, the world's first large language
More news about: Mana.bio
Sep 17, 2025, 09:00 ET Mana.bio Unveils Mina™,The World's First Large Language Model-Powered AI Agent for Lipid Nanoparticles
TEL AVIV, Israel, Sept. 17, 2025 /PRNewswire/ -- Mana.bio, a biotechnology company pioneering the intersection of artificial intelligence and RNA delivery, today announced the launch of Mina™, the world's first large language
More news about: Mana.bio
Sep 17, 2025, 09:00 ET Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Sep 17, 2025, 08:47 ET Frame Bio Licenses Novel Drug Delivery Technology from Mercury Bio to Develop Regenerative Therapies for Bone and Collagen Diseases and Disorders
Frame Bio, a biotechnology company developing therapeutics for structural diseases and disorders, announced today an exclusive licensing agreement with
More news about: Frame Bio LLC
Sep 17, 2025, 08:30 ET Advancing Cancer Research Brings New Hope for Patients Worldwide
and CEO Dr. Vuong Trieu, the company is applying AI, nanomedicine and innovative clinical approaches to reimagine biotechnology. Anchored by a strong intellectual property portfolio, including some 500 patent applications and 75 granted patents, Oncotelic is assembling a
More news about: NetworkNewsWire
Sep 17, 2025, 08:00 ET Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced positive results from the first interim
More news about: Skyhawk Therapeutics
Sep 17, 2025, 07:32 ET Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon Biologics
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
Spain, Sept. 17, 2025 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing targeted RNA medicines for rare genetic neuromuscular disorders, today announced the successful closing of its upsized
More news about: ARTHEx Biotech
Sep 16, 2025, 19:30 ET Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
until 2044 without patent extensions. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Sep 16, 2025, 18:01 ET Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company